Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
2.
Australas J Dermatol ; 62(4): e539-e545, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34424533

ABSTRACT

BACKGROUND: Atopic dermatitis (AD) is a common, chronic dermatosis, with onset of disease often manifesting in early infancy. Past studies evaluating the early use of moisturisers in the prevention of AD had mixed results. OBJECTIVES: To compare the incidence of moderate or severe AD and total incidence of AD in a cohort of 'at-risk' infants treated with moisturisers from the first 2 weeks of life, to a similar group without moisturisers. METHODS: We performed a single-centre, prospective, parallel-group, randomised study in infants with at least 2 first-degree relatives with atopy. Subjects were randomised into either a treatment group with moisturisers or a control group without moisturisers. Participants were assessed at 2, 6, and 12 months for AD and if present, the severity was assessed using SCORAD index. We also compared the overall incidence of AD, trans-epidermal water loss (TEWL), stratum corneum (SC) hydration, pH, and incidence of food and environmental sensitisation and allergies between both groups. Genotyping for loss-of-functions mutations in the FLG gene was conducted. RESULTS: A total of 200 subjects were recruited, with 100 subjects in each arm. There was no significant difference in incidence of moderate or severe AD, and total incidence of AD at 12 months between the treatment and control groups. There was a lower mean SCORAD in the treatment group than in the control group, but no significant difference in TEWL, SC hydration, and skin pH. No significant side-effects were reported. CONCLUSIONS: The early use of moisturisers in 'at-risk' infants does not reduce the incidence of moderate-to-severe AD and overall incidence of AD in infancy.


Subject(s)
Dermatitis, Atopic/epidemiology , Dermatitis, Atopic/prevention & control , Dermatologic Agents/administration & dosage , Ointments/administration & dosage , Propylene Glycols/administration & dosage , Skin Cream/administration & dosage , Sodium Dodecyl Sulfate/administration & dosage , Age Factors , Cohort Studies , Dermatitis, Atopic/diagnosis , Drug Combinations , Female , Humans , Incidence , Infant , Infant, Newborn , Male , Risk Factors
4.
J Cutan Pathol ; 45(7): 491-497, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29604103

ABSTRACT

BACKGROUND: There are patients with recalcitrant psoriasiform plaques that do not fit into conventional categories of facial dermatoses. Our study aims to describe the clinicopathological characteristics of several patients with a unique presentation of persistent psoriasiform facial rashes. METHODS: This retrospective cross-sectional study analyzed clinical and histological data of known cases of recalcitrant psoriasiform dermatosis of the face diagnosed at National Skin Centre, Singapore, over 10 years. RESULTS: There were 8 Chinese patients with mean age at onset of 29 years. Majority had pink to pink-orange well-defined plaques with dry scale (n = 6, 75%), distributed mostly on the cheeks (100%) and chin (n = 7, 88%). Hyperkeratosis, parakeratosis, preserved granular layer and psoriasiform hyperplasia were showed in all biopsies. Other common findings included subtle subcorneal acantholysis, "checkerboard" alternating ortho-/parakeratosis, vacuolated keratinocytes and follicular plugging. All patients showed little treatment response. One patient eventually developed features of type II pityriasis rubra pilaris (PRP). Our study was limited by its small sample size and lack of a pre-existing diagnostic code. CONCLUSIONS: This recalcitrant psoriasiform facial dermatosis seems to be a distinct entity, with consistent and reproducible clinical features and a PRP-like histology, bearing some resemblance to the recently described condition-facial discoid dermatosis.


Subject(s)
Facial Dermatoses/pathology , Pityriasis Rubra Pilaris/pathology , Adolescent , Adult , Biopsy , Cross-Sectional Studies , Facial Dermatoses/classification , Female , Humans , Male , Middle Aged , Pityriasis Rubra Pilaris/classification , Retrospective Studies
5.
Australas J Dermatol ; 59(4): 322-327, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29635779

ABSTRACT

BACKGROUND/OBJECTIVES: Controversy persists as to whether lichen planus pigmentosus and ashy dermatosis are separate clinical entities. This study was conducted to examine the clinicopathological features and treatment outcome of the two conditions. METHODS: A retrospective medical chart review of all patients who were diagnosed with lichen planus pigmentosus or ashy dermatosis was conducted. The information collected included the participants' age at onset, site of onset, duration of disease, presence of precipitating factors, distribution of disease, pigmentation and presence of symptoms. In patients from whom a biopsy was taken the histopathological reports were included. RESULTS: Altogether 26 patients with ashy dermatosis and 29 with lichen planus pigmentosus were included in the study. Compared with ashy dermatosis, lichen planus pigmentosus had a more localised distribution with a preponderance for facial involvement, compared with the truncal preponderance in ashy dermatosis. Ashy dermatosis tended to have a more stable clinical course than lichen planus pigmentosus, which was more likely to wax and wane. The utility of histopathology in differentiating between the two conditions is low. CONCLUSION: Ashy dermatosis and lichen planus pigmentosus, as defined in this study, appear to be two separate clinical entities with distinguishable clinical features and natural histories.


Subject(s)
Hyperpigmentation/drug therapy , Lichen Planus/drug therapy , Adolescent , Adult , Aged , Child , Disease Progression , Face , Female , Humans , Hyperpigmentation/ethnology , Hyperpigmentation/pathology , Lichen Planus/ethnology , Lichen Planus/pathology , Male , Middle Aged , Retrospective Studies , Torso , Treatment Outcome , Young Adult
7.
J Am Acad Dermatol ; 75(3): 564-571, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27180264

ABSTRACT

BACKGROUND: Noncultured cellular grafting is a known surgical technique for vitiligo. OBJECTIVE: This study evaluated our center's 12-month repigmentation outcome and its maintenance up to 60 months, factors influencing repigmentation and safety data. METHODS: Clinicoepidemiologic and repigmentation data were reviewed for patients with vitiligo who had undergone noncultured cellular grafting from March 2006 to December 2012 at the National Skin Center, Singapore. RESULTS: All 177 patients who received noncultured cellular grafting during the study period were included. For those with available data, good to excellent repigmentation was present in 83% at 60 months. At 12 months, 88% of patients (n = 52) with segmental vitiligo achieved good to excellent repigmentation compared with 71% (n = 55) with nonsegmental vitiligo (P < .05). More patients on collagen dressings (82%) achieved good to excellent repigmentation compared with those who received hyaluronic acid (63%) (P < .05). Sites of lesions and postgrafting phototherapy did not significantly affect repigmentation outcome. Adverse reactions were uncommon and mild. LIMITATIONS: The study is limited by its retrospective nature, the progressive loss to follow-up of patients, the absence of blinding, and the lack of use of standardized assessment tools. CONCLUSION: Noncultured cellular grafting was successful in allowing more than 80% of patients to achieve good to excellent repigmentation for at least 60 months.


Subject(s)
Epidermis/transplantation , Skin Pigmentation/physiology , Skin Transplantation/methods , Vitiligo/surgery , Adult , Databases, Factual , Epidermal Cells , Esthetics , Female , Follow-Up Studies , Graft Rejection , Graft Survival , Humans , Male , Middle Aged , Retrospective Studies , Risk Assessment , Severity of Illness Index , Singapore , Skin Transplantation/adverse effects , Tertiary Care Centers , Time Factors , Treatment Outcome , Vitiligo/diagnosis , Wound Healing/physiology , Young Adult
8.
J Am Acad Dermatol ; 74(6): 1178-84, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26830867

ABSTRACT

BACKGROUND: Follicular vitiligo, a recently proposed new subtype of vitiligo, has primary involvement of the hair follicle melanocytic reservoir. OBJECTIVE: We sought to characterize follicular vitiligo through a case series of 8 patients. METHODS: Patients with features of follicular vitiligo who were seen at the vitiligo clinic in the National Center for Rare Skin Disorders in Bordeaux, France, were recruited. A retrospective review of case records and clinical photographs was carried out. RESULTS: There were 8 male patients with a mean age of 48 years. All patients reported significant whitening of their body and, in some, scalp hairs before cutaneous depigmentation. Examination revealed classic generalized depigmented lesions of vitiligo and an impressive presence of leukotrichia, not only in the vitiliginous areas, but also in areas with clinically normal-appearing skin. Punch biopsy specimen of the leukotrichia and vitiligo lesions demonstrated loss of melanocytes and precursors in the basal epidermis and hair follicle. LIMITATIONS: This was a cross-sectional study based on a single-center experience. CONCLUSION: Follicular vitiligo is a distinct entity within the spectrum of vitiligo. This entity may serve as the missing link between alopecia areata and vitiligo, with probable physiopathological similarities between these conditions.


Subject(s)
Epidermis/pathology , Hair Color , Hair Follicle/pathology , Vitiligo/pathology , Adolescent , Adult , Biopsy , Child , Cross-Sectional Studies , Humans , Male , Melanocytes/pathology , Middle Aged , Retrospective Studies , Young Adult
10.
Australas J Dermatol ; 56(1): 1-6, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25178874

ABSTRACT

BACKGROUND/OBJECTIVES: Cutaneous metastases occur in up to 10% of all visceral malignancies. This study aims to determine the clinico-epidemiological characteristics of patients diagnosed with cutaneous metastases at a leading Asian tertiary dermatological centre. METHODS: A retrospective chart review was carried out on all patients diagnosed with cutaneous metastases from 2001 to 2010, identified through the National Skin Centre's clinical and histological databases. RESULTS: In all, 35 patients were diagnosed with cutaneous metastases at a mean age of 65 years, with a female: male ratio of 3:2 and with most (97%) being Chinese. Cutaneous metastases were the first presentation of cancer in 34% of patients (n = 12). The two commonest primaries were breast (49%, n = 17) and lung (9%, n = 3). Most had cutaneous metastases on the chest (37%, n = 13) followed by the pelvis (17%, n = 6) and 20% (n = 7) had skin lesions on multiple sites. Clinically, 46% of patients (n = 16) presented with nodule(s), 26% (n = 9) with plaque(s) and 20% (n = 7) with heterogeneous morphologies. Cutaneous metastases were suspected in 72% of patients (n = 25), attributed to clinical features (46%, n = 16) or the presence of active metastatic disease elsewhere (26%, n = 9). All lesions appeared dermal in origin. CONCLUSIONS: Cutaneous metastases are highly variable in presentation and a high index of suspicion is required for prompt diagnosis, especially in patients with a history of cancer, regardless of stage of treatment of the primary tumour.


Subject(s)
Adenocarcinoma/secondary , Breast Neoplasms/pathology , Carcinoma, Squamous Cell/secondary , Lung Neoplasms/pathology , Neoplasms, Unknown Primary/pathology , Skin Neoplasms/secondary , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Retrospective Studies , Singapore/epidemiology , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology
11.
BioDrugs ; 27(4): 359-73, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23580094

ABSTRACT

Psoriatic arthritis affects approximately 6-42 % of patients with psoriasis. It is useful for physicians or dermatologists managing psoriasis patients to be aware of how to concurrently manage the joint manifestations, as it is preferable and convenient to use a single agent in such patients. However, only certain therapies are effective for both. Systemic agents, which can be used for both skin and joint manifestations, include methotrexate and ciclosporin. For the group of biologic agents, the tumor necrosis factor inhibitors such as adalimumab, etanercept, infliximab, golimumab and certolizumab are effective. Ustekinumab is a more recently developed agent belonging to the group of anti-IL-12p40 antibodies and has been shown to be efficacious. Newer drugs in the treatment armamentarium that have shown efficacy for both psoriasis and psoriatic arthritis consist of the anti-IL-17 agent, secukinumab, and a phosphodiesterase-4 inhibitor, apremilast. The other anti-IL-17 agents, ixekizumab and brodalumab, as well as the oral Jak inhibitor, tofacitinib, have very limited but promising data. This review paper provides a good overview of the agents that can be used for the concurrent management of skin and joint psoriasis.


Subject(s)
Arthritis, Psoriatic/prevention & control , Biological Products/therapeutic use , Immunosuppressive Agents/therapeutic use , Joints/drug effects , Psoriasis/drug therapy , Skin/drug effects , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/adverse effects , Antirheumatic Agents/pharmacology , Antirheumatic Agents/therapeutic use , Arthritis, Psoriatic/drug therapy , Arthritis, Psoriatic/etiology , Arthritis, Psoriatic/immunology , Biological Products/adverse effects , Biological Products/pharmacology , Dermatologic Agents/adverse effects , Dermatologic Agents/pharmacology , Dermatologic Agents/therapeutic use , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/pharmacology , Interleukin-12 Subunit p40/antagonists & inhibitors , Interleukin-12 Subunit p40/metabolism , Interleukin-17/antagonists & inhibitors , Interleukin-17/metabolism , Janus Kinases/antagonists & inhibitors , Janus Kinases/metabolism , Joints/immunology , Joints/metabolism , Phosphodiesterase 4 Inhibitors/adverse effects , Phosphodiesterase 4 Inhibitors/pharmacology , Phosphodiesterase 4 Inhibitors/therapeutic use , Protein Kinase Inhibitors/adverse effects , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/therapeutic use , Psoriasis/immunology , Psoriasis/metabolism , Psoriasis/physiopathology , Recombinant Fusion Proteins/adverse effects , Recombinant Fusion Proteins/pharmacology , Recombinant Fusion Proteins/therapeutic use , Skin/immunology , Skin/metabolism , Tumor Necrosis Factor Inhibitors , Tumor Necrosis Factors/metabolism
12.
Am J Clin Dermatol ; 14(2): 77-85, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23456596

ABSTRACT

Herpes zoster and its sequela post-herpetic neuralgia (PHN) are conditions with significant morbidity. PHN is a chronic, debilitating neuropathic pain that can persist long beyond resolution of visible cutaneous manifestations. This paper provides practical guidelines for management of herpes zoster and PHN. For herpes zoster, antivirals should be started, preferably within 72 h of onset, to reduce the severity and duration of the eruptive phase and to reduce the intensity of acute pain. PHN can be treated with either topical or systemic agents. Topical lidocaine and capsaicin are effective. For patients with more severe pain, the following systemic agents can be considered (in decreasing order of recommendation): the anticonvulsants gabapentin and pregabalin, the tricyclic antidepressants amitriptyline, nortriptyline, and desipramine, and, lastly, the opioid analgesics tramadol, morphine, oxycodone, and methadone. For patients at high risk of developing PHN, early initiation of gabapentin or amitriptyline after the onset of herpes zoster is suggested. The new zoster vaccine has been shown to be effective in reducing the incidence of herpes zoster and PHN.


Subject(s)
Herpes Zoster/therapy , Neuralgia, Postherpetic/therapy , Ultraviolet Therapy/methods , Adrenal Cortex Hormones/therapeutic use , Analgesics, Opioid/therapeutic use , Antiviral Agents/therapeutic use , Combined Modality Therapy , Evidence-Based Medicine , Female , Herpes Zoster/complications , Herpes Zoster/diagnosis , Humans , Male , Neuralgia, Postherpetic/etiology , Neuralgia, Postherpetic/physiopathology , Pain Measurement , Prognosis , Randomized Controlled Trials as Topic , Risk Assessment , Severity of Illness Index , Treatment Outcome
13.
J Dermatolog Treat ; 24(5): 387-91, 2013 Oct.
Article in English | MEDLINE | ID: mdl-22390469

ABSTRACT

BACKGROUND: Oral isotretinoin is effective for acne vulgaris but concerns remain regarding its adverse effects. OBJECTIVES: This study aims to evaluate the safety and efficacy of isotretinoin for acne vulgaris in Asian patients. METHODS: We conducted a 4-year retrospective study on all patients with acne vulgaris treated with isotretinoin, between January 2005 and December 2008 at the National Skin Centre in Singapore. Medical records were reviewed for information on patient demographics, acne severity, isotretinoin dose, duration, adverse effects and outcome. RESULTS: There were 2,255 patients, with a mean age of 22.5 years, male:female ratio of 2.5:1 and 82.3% being Chinese. The mean starting dose of isotretinoin was 0.4 mg/kg and on average, patients received 7.8 months of treatment at a mean dose of 0.5 mg/kg. Mean total cumulative dose was 95.6 mg/kg. Vast majority (93.9%) achieved complete remission or substantial improvement. Thirty-eight (2.2%) and 24 patients (2.7%) developed elevated serum levels of alanine and aspartate aminotransferases subsequent to treatment. There were 194 (12.1%) and 80 (4.8%) patients who developed hyperlipidaemia and hypertriglyceridaemia respectively. Isotretinoin was generally well-tolerated, with 6.4% (n = 145) discontinuing due to side-effects. CONCLUSIONS: This study reaffirms the overall safety and efficacy of oral isotretinoin in Asian patients with acne vulgaris.


Subject(s)
Acne Vulgaris/drug therapy , Dermatologic Agents/therapeutic use , Isotretinoin/therapeutic use , Acne Vulgaris/ethnology , Administration, Oral , Adolescent , Adult , Asian People , Child , Cohort Studies , Female , Humans , Male , Middle Aged , Retrospective Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...